摘要
背景:多形性成胶质细胞瘤(GBM)持续侵害患者,尽管临床医师对其生物学、发病机制和治疗进展进行了研究,研究人员仍难以控制该类肿瘤。相比于原肿瘤,GBM具有明显的基因差异性,它不可避免地以一种更加侵略性和耐药性的方式复发,常规性地比较多原则治疗方案活的更久。为了进一步不断获得更多信息将GBM点朝类干细胞表型的方向发展。这些癌肿肝细胞与目前大多数恶性肿瘤类似,能够在许多易感肿瘤中发生。 结论:胶质瘤干细胞由其肿瘤的发展、修复和复发的预期研究因此也变成了当前研究热点。胶质瘤干细胞能够浸润肿瘤周围白质,常常难以被切除。特殊的是,他们在生化和环境方面能够抵抗当前可利用的最好的治疗,本能地及有效地抵制标准化疗和放疗。这些胶质瘤干细胞产生了一种异源性肿瘤以致到目前为止每一种治疗性的问题都有一个答案,患者的死亡率仍较低。针对胶质瘤干细胞的患者进行研究可能是在GBM中达到持久疗效的关键。
关键词: 化疗,药物靶向,多形性成胶质细胞瘤,胶质瘤干细胞,生态位,阻力,重现
图形摘要
Current Cancer Drug Targets
Title:Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Volume: 17 Issue: 3
关键词: 化疗,药物靶向,多形性成胶质细胞瘤,胶质瘤干细胞,生态位,阻力,重现
摘要: Background: Glioblastoma multiforme (GBM) continues to devastate patients and outfox investigators and clinicians despite the preponderance of research directed at its biology, pathogenesis and therapeutic advances. GBM routinely outlasts multidisciplinary treatment protocols, almost inevitably recurring in a yet more aggressive and resistant form with distinct genetic differences from the original tumor. Attempts to glean further insight into GBM point increasingly toward a subpopulation of cells with a stem-like phenotype. These cancer stem cells, similar to those now described in a variety of malignancies, are capable of tumorigenesis from a population of susceptible cells.
Conclusions: Glioma stem cells have thus become a prevalent focus in GBM research for their presumed role in development, maintenance and recurrence of tumors. Glioma stem cells infiltrate the white matter surrounding tumors and often evade resection. They are uniquely suited both biochemically and environmentally to resist the best therapy currently available, intrinsically and efficiently resistant to standard chemo- and radiotherapy. These stem cells create an extremely heterogenous tumor that to date has had an answer for every therapeutic question, with continued dismal patient survival. Targeting this population of glioma stem cells may hold the long-awaited key to durable therapeutic efficacy in GBM.Export Options
About this article
Cite this article as:
Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy, Current Cancer Drug Targets 2017; 17 (3) . https://dx.doi.org/10.2174/1568009616666161215161924
DOI https://dx.doi.org/10.2174/1568009616666161215161924 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Application of Baculovirus-Insect Cell Expression System for Human Therapy
Current Pharmaceutical Biotechnology Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers
Current Pharmaceutical Design Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology Role of TGF- β in the Tumor Stroma
Current Cancer Drug Targets Recent Progress in Stimuli-Responsive Intelligent Nano Scale Drug Delivery Systems: A Special Focus Towards pH-Sensitive Systems
Current Drug Targets Human- and Virus-Encoded microRNAs as Potential Targets of Antiviral Therapy
Mini-Reviews in Medicinal Chemistry Matrix Metalloproteinases: A Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design <sup>90</sup>Y-DOTA-Nimotuzumab: Synthesis of a Promising β− Radiopharmaceutical
Current Radiopharmaceuticals Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Drug Metabolism Letters Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Current Stem Cell Research & Therapy